Moerae Matrix: <b>Moerae</b> Initiates Lipopolysaccharide (LPS) Challenge Study Of Inhaled MMI-0100 For Pulmonary Disease Following Encouraging Safety And Tolerability Observed In Single Ascending Dose Phase 1 Study

MORRISTOWN, N.J., July 28, 2015 /PRNewswire/ --Moerae Matrix Inc. announced today the initiation of its second Phase 1 clinical trial with MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 (MK2) that is being developed for pulmonary disorders characterized by inflammation and fibrosis. The study, conducted...